A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

por Verstovsek, Srdan, Courby, Stephane, Griesshammer, Martin, Mesa, Ruben A., Brachmann, Carrie Baker, Kawashima, Jun, Maltzman, Julia D., Shao, Lixin, Xin, Yan, Huang, Daniel, Bajel, Ashish
Publicado 2017

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors

por Necela, Brian M., Crozier, Jennifer A., Andorfer, Cathy A., Lewis-Tuffin, Laura, Kachergus, Jennifer M., Geiger, Xochiquetzal J., Kalari, Krishna R., Serie, Daniel J., Sun, Zhifu, Aspita, Alvaro Moreno, O’Shannessy, Daniel J., Maltzman, Julia D., McCullough, Ann E., Pockaj, Barbara A., Cunliffe, Heather E., Ballman, Karla V., Thompson, E. Aubrey, Perez, Edith A.
Publicado 2015

Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors

por Necela, Brian M., Crozier, Jennifer A., Andorfer, Cathy A., Lewis-Tuffin, Laura, Kachergus, Jennifer M., Geiger, Xochiquetzal J., Kalari, Krishna R., Serie, Daniel J., Sun, Zhifu, Moreno-Aspitia, Alvaro, O’Shannessy, Daniel J., Maltzman, Julia D., McCullough, Ann E., Pockaj, Barbara A., Cunliffe, Heather E., Ballman, Karla V., Thompson, E. Aubrey, Perez, Edith A.
Publicado 2015